

Election of the chair of the Meeting (item 2)

The Nomination Committee of Swedish Orphan Biovitrum AB (publ), which consists of Daniel Nodhäll, chair (Investor AB), Annette Clancy (chair of the Board of Directors), Thomas Ehlin (The Fourth Swedish National Pension Fund (AP4)) and Niklas Johansson (Handelsbanken Fonder AB), proposes that attorney-at-law Emil Boström from Mannheimer Swartling Advokatbyrå is elected chair of the Meeting.

Fees for the members of the Board of Directors and the auditor (item 13)

The Nomination Committee proposes the following:¹

- that fees to be paid to the Board of Directors should be SEK 1,885,000 (1,725,000) to the chair of the Board of Directors and SEK 625,000 (570,000) to each of the other members of the Board of Directors elected by the Annual General Meeting, that fees for work in the Audit Committee should be SEK 235,000 (190,000) to the chair and SEK 135,000 (110,000) to each other member of such committee, that fees for work in the Compensation & Benefits Committee should be SEK 150,000 (125,000) to the chair and SEK 100,000 (80,000) to each other member of such committee, that fees for work in the Scientific Committee should be SEK 150,000 (125,000) to the chair and SEK 100,000 (80,000) to each other member of such committee, and that fees for work in another committee in accordance with a decision by the Board of Directors (for example Transaction Committee) should be SEK 150,000 (80,000) to the chair and SEK 100,000 (80,000) to each other member of such committee,
- that, in addition to the fees proposed above, for each physical meeting of the Board of Directors held in Sweden, a meeting fee of EUR 2,000 (SEK 20,000) is paid to the members of the Board of Directors that reside in Europe outside the Nordic countries and a meeting fee of USD 3,500 (unchanged) is paid to the members of the Board of Directors that reside outside Europe, and
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice.

The number of members of the Board of Directors, deputy directors, auditors and deputy auditors (item 14)

The Nomination Committee proposes the following:

- that seven ordinary members of the Board of Directors without deputies should be appointed, and
- that one auditor without any deputy auditor should be appointed.

¹ Figures within parenthesis refer to fees for the corresponding period the previous year.

Election of the chair, the members of the Board of Directors and the auditor (item 15)

The Nomination Committee proposes the following:

- that Christophe Bourdon, Annette Clancy, Helena Saxon, Staffan Schüberg, Filippa Stenberg and Anders Ullman should be re-elected as ordinary members of the Board of Directors, that Zlatko Rihter should be elected as new ordinary member of the Board of Directors and that Annette Clancy should be elected as chair of the Board of Directors, and
- that Ernst & Young AB should be re-elected as auditor of the company until the end of the Annual General Meeting 2025, in accordance with the Audit Committee's recommendation.

Zlatko Rihter

Zlatko Rihter (born 1970) holds a Master of Science in Mechanical Engineering from Lund University, Sweden.

Zlatko is CEO of Mölnlycke Health Care AB. He has more than 25 years of experience within the health care sector and his previous experience includes President and CEO at CellaVision, Executive Vice President Sales & Marketing at ORIGIO, President GBU Chronic at Gambro and Director Patient Handling Product Division at ArjoHuntleigh. He was also a Board member of Malmö FF and of Etac Group.

The Nomination Committee recommends the elected Board members to build their own holdings of shares in the company

Similar to previous years, the Nomination Committee recommends the Board of Directors of Swedish Orphan Biovitrum AB (publ) to establish a shareholding policy pursuant to which the members of the Board of Directors, who do not already have such holdings, are expected to, over a five year period, acquire an ownership in Swedish Orphan Biovitrum AB (publ) shares with a market value which is expected to correspond to at least one year board remuneration, before taxes, excluding remuneration for committee work.

The Nomination Committee's proposal for election of auditor

The Nomination Committee proposes, in accordance with the recommendation from the Audit Committee, the re-election of Ernst & Young AB as the company's auditor until the end of the Annual General Meeting 2025.

Swedish Orphan Biovitrum AB (publ) has performed a tender process ahead of the election of auditor at the Annual General Meeting 2024. After an overall assessment, thoroughly analysing and weighing the selection criteria (including competence and mix of audit team, engagement

and accessibility, sector experience, global reach, audit model including tools and automation, quality assurance, independence/conflict of interest, expertise within sustainability and cyber and information security, transition plan as well as audit fees and impressions from presentations), the Audit Committee has resolved to recommend the re-election of Ernst & Young AB as the company's auditor until the end of the Annual General Meeting 2025. In the event that Ernst & Young AB is not re-elected as the company's auditor, the Audit Committee has resolved to recommend, as a second alternative, the election of KPMG AB as the company's auditor until the end of the Annual General Meeting 2025. The Nomination Committee has been informed that the Board of Directors of Swedish Orphan Biovitrum AB (publ) has endorsed the recommendation of the Audit Committee.